As of November 6, 2026, Annexon, Inc. is a publicly traded company (Nasdaq: ANNX). The largest holder reporting an active stake on Schedule 13D is Muneer A. Satter, a director, at 7.2%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (13.9%), Redmile Group, LLC (9.9%), BlackRock (8%) (Schedule 13D/A, November 21, 2025).
Is this your company?
About to sign with, pay or invest in Annexon, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Annexon, Inc. a real, registered company?
- Annexon, Inc. files with the SEC under CIK 1528115 (its SEC filings).
- Its shares are listed under the ticker ANNX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Brisbane, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ANNEXON INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Muneer Satter, Director (Form 8-K filed 2026-08-10). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Annexon, Inc.'s owners and officers?
Annexon, Inc.: incorporated in Delaware; business address in Brisbane, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 13.9% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 6% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 8% |
| Schedule 13G/A, 2026-07-08 | Fmr LLC | 11.9% |
| Schedule 13G/A, 2026-07-08 | Redmile Group, LLC | 9.9% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 5.4% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Redmile Group, LLC | 9.9% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 7.1% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 6.1% |
| Schedule 13D/A, 2025-11-21 | Satter Muneer A | 7.2% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 10.1% |
Questions about who owns Annexon, Inc.
Who owns Annexon, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Annexon, Inc.: Fmr LLC (13.9%, Schedule 13G/A, filed 2026-11-05), Redmile Group, LLC (9.9%, Schedule 13G/A, filed 2026-07-08), Blackrock, Inc. (8%, Schedule 13G/A, filed 2026-07-27), Satter Muneer A (7.2%, Schedule 13D/A, filed 2025-11-21) and State Street Corporation (6%, Schedule 13G, filed 2026-08-07); 1 more is listed above.
Who are the largest shareholders of Annexon, Inc.?
By the share each holder's latest filing reports, the largest holders of Annexon, Inc. on this page are Fmr LLC (13.9%), Redmile Group, LLC (9.9%) and Blackrock, Inc. (8%).
When did Fmr LLC buy into Annexon, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-11-05, reporting 10.1%; its latest, Schedule 13G/A filed 2026-11-05, reports 13.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Annexon, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Annexon, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Annexon, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-10 | Muneer Satter | Director | departed | |
| Form 8-K, 2026-08-10 | Mark S. Blumenkranz | appointed |
Which insiders own Annexon, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 10,342,134 shares (26.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-05-29).
- , the chief executive and president: 390,476 shares (1.0% of shares outstanding) (Form 4, 2026-09-25).
- , the executive vice president and chief innovation officer: 184,807 shares (0.48% of shares outstanding) (Form 4, 2026-06-15).
- , the executive vice president and chief business officer: 182,625 shares (0.47% of shares outstanding) (Form 4, 2026-03-04).
- , the executive vice president and chief scientific officer: 180,093 shares (0.47% of shares outstanding) (Form 4, 2026-03-04).
Shares outstanding: 38,563,565 as of 2022-05-02, from the company's latest SEC cover page.
How much has Annexon, Inc. raised?
No fundraising or offering filing from Annexon, Inc. is on file with us.
Keep reading
More on Annexon, Inc. and the records around it.
Annexon, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Aug 2026
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/annexon